{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:56Z","timestamp":1790188196748,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is a paucity of evidence supporting the use of adjuvant radiation therapy in resected biliary cancer. Supporting evidence for use comes mainly from the small SWOG S0809 trial, which demonstrated an overall median survival of 35 months. We aimed to use a large national database to evaluate the use of adjuvant chemoradiation in resected extrahepatic bile duct and gallbladder cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the National Cancer Database, we selected patients from 2004 to 2017 with pT2-4, pN0-1, M0 extrahepatic bile duct or gallbladder adenocarcinoma with either R0 or R1 resection margins, and examined factors associated with overall survival (OS). We examined OS in a cohort of patients mimicking the SWOG S0809 protocol as a large validation cohort. Lastly, we compared patients who received chemotherapy only with patients who received adjuvant chemotherapy and radiation using entropy balancing propensity score matching.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 4997 patients with gallbladder or extrahepatic bile duct adenocarcinoma with available survival information meeting the SWOG S0809 criteria were selected, 469 of whom received both adjuvant chemotherapy and radiotherapy. Median OS in patients undergoing chemoradiation was 36.9 months, and was not different between primary sites (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.841). In a propensity score matched cohort, receipt of adjuvant chemoradiation had a survival benefit compared with adjuvant chemotherapy only (hazard ratio 0.86, 95% confidence interval 0.77\u20130.95; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.004).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Using a large national database, we support the findings of SWOG S0809 with a similar median OS in patients receiving chemoradiation. These data further support the consideration of adjuvant multimodal therapy in resected biliary cancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15117-y","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:01:46Z","timestamp":1709661706000},"page":"4896-4904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database"],"prefix":"10.1245","volume":"31","author":[{"given":"Dana A.","family":"Dominguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H. G.","family":"Ituarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-7981","authenticated-orcid":false,"given":"Laleh G.","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"2","key":"15117_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/jgo.2016.10.01","volume":"8","author":"DH Ahn","year":"2017","unstructured":"Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017;8(2):293\u2013301. https:\/\/doi.org\/10.21037\/jgo.2016.10.01.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"15117_CR2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, Klimstra D, D\u2019Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689\u2013700. https:\/\/doi.org\/10.1002\/cncr.11699.","journal-title":"Cancer"},{"issue":"2","key":"15117_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"issue":"5","key":"15117_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"issue":"10372","key":"15117_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(22)02038-4.","journal-title":"Lancet"},{"issue":"14","key":"15117_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"12","key":"15117_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02178.","journal-title":"J Clin Oncol"},{"issue":"24","key":"15117_CR8","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.60.2219.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15117_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2012","unstructured":"Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25\u201346. https:\/\/doi.org\/10.1093\/pan\/mpr025.","journal-title":"Polit Anal"},{"key":"15117_CR10","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v054.i07","author":"J Hainmueller","year":"2013","unstructured":"Hainmueller J, Xu Y. Ebalance: a Stata package for entropy balancing. J Stat Softw. 2013. https:\/\/doi.org\/10.18637\/jss.v054.i07.","journal-title":"J Stat Softw"},{"issue":"4","key":"15117_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ijrobp.2017.06.2467","volume":"99","author":"Z Ghiassi-Nejad","year":"2017","unstructured":"Ghiassi-Nejad Z, Tarchi P, Moshier E, Ru M, Tabrizian P, Schwartz M, et al. Prognostic factors and patterns of locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: optimal field design for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(4):805\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2467.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15117_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.radonc.2020.03.017","volume":"147","author":"W Zhou","year":"2020","unstructured":"Zhou W, Qian L, Rong Y, Zhou Q, Shan J, Li P, et al. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol. 2020;147:111\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.017.","journal-title":"Radiother Oncol"},{"issue":"2","key":"15117_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147\u201356. https:\/\/doi.org\/10.1001\/jama.2012.7352.","journal-title":"JAMA"},{"issue":"3","key":"15117_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1245\/s10434-022-12863-9","volume":"30","author":"S Gholami","year":"2023","unstructured":"Gholami S, Colby S, Horowitz DP, Guthrie KA, Ben-Josef E, El-Khoueiry AB, et al. Adjuvant chemoradiation in patients with lymph node-positive biliary tract cancers: secondary analysis of a single-arm clinical trial (SWOG 0809). Ann Surg Oncol. 2023;30(3):1354\u201363. https:\/\/doi.org\/10.1245\/s10434-022-12863-9.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"15117_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1245\/s10434-022-12865-7","volume":"30","author":"SG Warner","year":"2023","unstructured":"Warner SG, Starlinger P. Comparing apples to oranges: commentary on a secondary analysis of SWOG 0809. Ann Surg Oncol. 2023;30(3):1285\u20136. https:\/\/doi.org\/10.1245\/s10434-022-12865-7.","journal-title":"Ann Surg Oncol"},{"key":"15117_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2021.07.045","volume":"157","author":"K Kim","year":"2021","unstructured":"Kim K, Yu JI, Jung W, Kim TH, Seong J, Kim WC, et al. Role of adjuvant radiotherapy in extrahepatic bile duct cancer: a multicenter retrospective study (Korean radiation oncology group 18\u201314). Eur J Cancer. 2021;157:31\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.045.","journal-title":"Eur J Cancer"},{"issue":"2","key":"15117_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijrobp.2021.05.012","volume":"111","author":"WI Chang","year":"2021","unstructured":"Chang WI, Kim BH, Kang HC, Kim K, Lee KH, Oh DY, et al. The role of adjuvant chemoradiotherapy in nonhilar extrahepatic bile duct cancer: a long-term single-institution analysis. Int J Radiat Oncol Biol Phys. 2021;111(2):395\u2013404. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"15117_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jso.21544","volume":"102","author":"SY Cho","year":"2010","unstructured":"Cho SY, Kim SH, Park SJ, Han SS, Kim YK, Lee KW, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010;102(1):87\u201393. https:\/\/doi.org\/10.1002\/jso.21544.","journal-title":"J Surg Oncol"},{"issue":"6","key":"15117_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/cncr.34625","volume":"129","author":"R Shridhar","year":"2023","unstructured":"Shridhar R, Blinn P, Huston J, Meredith KL. Outcomes of adjuvant radiation therapy after chemotherapy in resected extrahepatic cholangiocarcinoma: a national cancer database analysis. Cancer. 2023;129(6):890\u2013900. https:\/\/doi.org\/10.1002\/cncr.34625.","journal-title":"Cancer"},{"issue":"8","key":"15117_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367. https:\/\/doi.org\/10.1200\/JCO.18.00050.","journal-title":"J Clin Oncol"},{"key":"15117_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15117-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T21:01:36Z","timestamp":1720645296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["15117"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15117-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yuman Fong is a scientific consultant to Medtronics, Eureka, Vergent, Imugene, Theromics, and Savato, and has received royalties from Merck, Imugene, and Xdemics. Dana A. Dominguez, Paul Wong, Yi-Jen Chen, Gagandeep P. Singh, Daneng Li, Philip H.G. Ituarte, and Laleh G. Melstrom have no disclosures to declare in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}